Drug – bio-affecting and body treating compositions – Radionuclide or intended radionuclide containing; adjuvant... – In an organic compound
Reexamination Certificate
2006-01-24
2006-01-24
Russel, Jeffrey Edwin (Department: 1654)
Drug, bio-affecting and body treating compositions
Radionuclide or intended radionuclide containing; adjuvant...
In an organic compound
C424S001690, C514S019300, C514S183000, C534S010000
Reexamination Certificate
active
06989139
ABSTRACT:
Thus the present invention describes novel compounds comprising 1-10 targeting moieties; a chelator (Ch); and 0-1 linking groups (Ln) between the targeting moiety and chelator; wherein the targeting moiety is a matrix metalloproteinase inhibitor; and wherein the chelator is capable of conjugating to a cytotoxic radioisotope. The present invention also provides novel compositions of the compounds of the invention, kits and their uses in treatment of diseases associated with MMPs.
REFERENCES:
patent: 5382654 (1995-01-01), Lyle et al.
patent: 5556939 (1996-09-01), Flanagan et al.
patent: 5646167 (1997-07-01), MacPherson et al.
patent: 5650134 (1997-07-01), Albert et al.
patent: 5674754 (1997-10-01), Ahrens et al.
patent: 6172057 (2001-01-01), Venkatesan et al.
patent: 6656448 (2003-12-01), Carpenter et al.
patent: 2002/0004032 (2002-01-01), Liu
patent: 2002/0098149 (2002-07-01), Liu
patent: 2003/0073808 (2003-04-01), Quirk et al.
patent: 0649658 (1995-04-01), None
patent: WO 97/18207 (1997-05-01), None
patent: WO 98/47541 (1998-10-01), None
patent: WO 99/18074 (1999-04-01), None
patent: WO 99/58162 (1999-11-01), None
patent: WO 99/65867 (1999-12-01), None
U.S. Appl. No. 60/195,234, filed Apr. 7, 2000.
M. Rajopadhye et al., Bioorg. Med. Chem. Lett., vol. 6, no 15, 1996, pp1737-1740.
Bakker et al. Life Sci., 1991, 49, 1583-91.
Garbisa et al., 1992, Cancer Res., 53, 4548-4549.
Matthes et al., 1992, Gastroenterology, Abstract 661.
Anthony et al., 1992, Gastroenterology, Abstract 591.
Walakovits et al., 1992, Arth. Rheum., 35, 35-42.
Zucker et al., 1993, Cancer Res. 53, 140-146.
Krenning, et al., 1993, Eur. J. Nucl. Med., 20, 716-31.
Curr. Opin. Ther. Patents 1994 4(1):7-16.
Exp. Opin. Ther. Patents 1995 5, 1087-1100.
Exp. Opin. Ther. Patents 1995 5,(12):1287-1196.
Curr. Medicinal Chem. 1995, 2, 743-762.
Krenning, et al., 1996, Digestion, 57, 57-61.
Beckett et al. 1996, Research Focus, 1, 16-26.
Summers, et al, Annual reports in Med. Chem., 1998, 33, 131-140.
Stein et al., 1999, Clin. Cancer Res., 5, 3199s-3206s.
Whittaker. et al, Chem. Rev., 1999, 99, 2735-2776.
Barrett John A.
Carpenter Jr. Alan P.
Decicco Carl P.
Duan Jingwu
Nelson David J.
Bristol-Myers Squibb Pharma Company
Russel Jeffrey Edwin
Volles Warren E.
Woodcock & Washburn LLP
LandOfFree
Matrix metalloproteinase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Matrix metalloproteinase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Matrix metalloproteinase inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3586964